OBJECTIVE: Our objective was to investigate cross-sectional and longitudinal associations of sex hormone concentrations with ankle-brachial index (ABI) and peripheral arterial disease (PAD). METHODS AND RESULTS: We used data from 3034 (1612 women) participants of the Framingham Heart Study. ABI was measured and PAD defined as ABI below 0.90, intermittent claudication, or lower extremity revascularization. Sex hormone concentrations were measured by liquid chromatography-tandem mass spectrometry [total testosterone (T), total estradiol, and estrone], immunofluorometric assay (SHBG), or calculated (free T). Sex-specific multivariable linear and logistic regression models were conducted for each sex hormone separately. Cross-sectional multivariable analyses revealed that men with lower free T and higher estrone (E1) concentrations had a significantly lower ABI [for free T, lowest vs. higher quartiles, β = -0.02, with 95% confidence interval (CI) = -0.04 to -0.001; and for E1, highest vs. lower quartiles, β = -0.02, with 95% CI = -0.04 to -0.002, respectively). Lower total T and SHBG concentrations were also associated with prevalent PAD in age-adjusted [odds ratio (OR) = 2.24, 95% CI = 1.17-4.32; and OR = 2.06; 95% CI = 1.07-3.96, lowest vs. highest quartile, respectively), but not in multivariable logistic regression models. Longitudinal multivariable analyses showed an association of lower SHBG with ABI change (decline ≥ 0.15; n = 69) in men [OR for SHBG quartiles 1, 2, and 3 as compared with quartile 4 were 2.56 (95% CI = 1.01-6.45), 2.28 (95% CI = 0.98-5.32), and 2.93 (95% CI = 1.31-6.52), respectively]. In women, none of the investigated associations yielded statistically significant estimates. CONCLUSION: Our investigation of a middle-aged community-based sample suggests that sex hormone concentrations in men but not in women may be associated with PAD and ABI change.
OBJECTIVE: Our objective was to investigate cross-sectional and longitudinal associations of sex hormone concentrations with ankle-brachial index (ABI) and peripheral arterial disease (PAD). METHODS AND RESULTS: We used data from 3034 (1612 women) participants of the Framingham Heart Study. ABI was measured and PAD defined as ABI below 0.90, intermittent claudication, or lower extremity revascularization. Sex hormone concentrations were measured by liquid chromatography-tandem mass spectrometry [total testosterone (T), total estradiol, and estrone], immunofluorometric assay (SHBG), or calculated (free T). Sex-specific multivariable linear and logistic regression models were conducted for each sex hormone separately. Cross-sectional multivariable analyses revealed that men with lower free T and higher estrone (E1) concentrations had a significantly lower ABI [for free T, lowest vs. higher quartiles, β = -0.02, with 95% confidence interval (CI) = -0.04 to -0.001; and for E1, highest vs. lower quartiles, β = -0.02, with 95% CI = -0.04 to -0.002, respectively). Lower total T and SHBG concentrations were also associated with prevalent PAD in age-adjusted [odds ratio (OR) = 2.24, 95% CI = 1.17-4.32; and OR = 2.06; 95% CI = 1.07-3.96, lowest vs. highest quartile, respectively), but not in multivariable logistic regression models. Longitudinal multivariable analyses showed an association of lower SHBG with ABI change (decline ≥ 0.15; n = 69) in men [OR for SHBG quartiles 1, 2, and 3 as compared with quartile 4 were 2.56 (95% CI = 1.01-6.45), 2.28 (95% CI = 0.98-5.32), and 2.93 (95% CI = 1.31-6.52), respectively]. In women, none of the investigated associations yielded statistically significant estimates. CONCLUSION: Our investigation of a middle-aged community-based sample suggests that sex hormone concentrations in men but not in women may be associated with PAD and ABI change.
Authors: Joanne M Murabito; Jane C Evans; Kenneth Nieto; Martin G Larson; Daniel Levy; Peter W f Wilson Journal: Am Heart J Date: 2002-06 Impact factor: 4.749
Authors: S Bhasin; T W Storer; M Javanbakht; N Berman; K E Yarasheski; J Phillips; M Dike; I Sinha-Hikim; R Shen; R D Hays; G Beall Journal: JAMA Date: 2000-02-09 Impact factor: 56.272
Authors: Robert P Byington; Curt D Furberg; David M Herrington; J Alan Herd; Donald Hunninghake; Maureen Lowery; Ward Riley; Timothy Craven; Lily Chaput; Christine C Ireland; William B Applegate Journal: Arterioscler Thromb Vasc Biol Date: 2002-10-01 Impact factor: 8.311
Authors: Helaine E Resnick; Robert S Lindsay; Mary McGrae McDermott; Richard B Devereux; Kristina L Jones; Richard R Fabsitz; Barbara V Howard Journal: Circulation Date: 2004-02-17 Impact factor: 29.690
Authors: Thomas G Travison; Christopher J O'Donnell; Shalender Bhasin; Joseph M Massaro; Udo Hoffmann; Ramachandran S Vasan; Ralph B D'Agostino; Shehzad Basaria Journal: J Clin Endocrinol Metab Date: 2016-03-01 Impact factor: 5.958
Authors: M Maggio; C Cattabiani; F Lauretani; A Artoni; S Bandinelli; G Schiavi; A Vignali; R Volpi; G Ceresini; G Lippi; R Aloe; F De Vita; F Giallauria; M M McDermott; L Ferrucci; G P Ceda Journal: Atherosclerosis Date: 2012-10-03 Impact factor: 5.162
Authors: João Henrique Fonseca do Nascimento; André Gusmão Cunha; André Bouzas de Andrade; Monique Magnavita Borba da Fonseca Cerqueira Journal: J Vasc Bras Date: 2022-01-07
Authors: Claes Ohlsson; Maria E Nilsson; Asa Tivesten; Henrik Ryberg; Dan Mellström; Magnus K Karlsson; Östen Ljunggren; Fernand Labrie; Eric S Orwoll; David M Lee; Stephen R Pye; Terence W O'Neill; Joseph D Finn; Judith E Adams; Kate A Ward; Steven Boonen; Gyorgy Bartfai; Felipe F Casanueva; Gianni Forti; Aleksander Giwercman; Thang S Han; Ilpo T Huhtaniemi; Krzysztof Kula; Michael E J Lean; Neil Pendleton; Margus Punab; Dirk Vanderschueren; Frederick C W Wu; Liesbeth Vandenput Journal: J Clin Endocrinol Metab Date: 2013-04-30 Impact factor: 5.958